Digital Pathology News | Tissuepathology.com

Gestalt: Why Healthcare IT Staff Augmentation Is Replacing Traditional Hiring in 2026

Erica Goodpaster — Mon, 24 Aug 2026 12:37:51 +0000

From the Gestalt blog: Healthcare IT isn’t shrinking, it’s resetting. After the surge of pandemic-era hiring, many health systems are stepping back and asking a hard question: does more headcount actually make us more agile? In 2026, with tighter margins, AI initiatives accelerating, and cybersecurity demands rising, the answer often isn’t yes. Fixed labor costs can […]

The post Gestalt: Why Healthcare IT Staff Augmentation Is Replacing Traditional Hiring in 2026 first appeared on Tissuepathology.com.

Proscia: Getting to Know Kary Rogers: A Conversation with Proscia’s Head of Support

Erica Goodpaster — Fri, 21 Aug 2026 11:58:09 +0000

From Proscia on LinkedIn When evaluating an enterprise pathology platform, many life sciences organizations and diagnostic laboratories focus on the features it offers. This makes sense since scientists and pathologists will rely on that functionality every day. At Proscia, we believe that product functionality is one important part of the experience that we deliver to […]

The post Proscia: Getting to Know Kary Rogers: A Conversation with Proscia’s Head of Support first appeared on Tissuepathology.com.

Bioptimus partners with Cancer Research Horizons to advance AI-powered precision medicine

Erica Goodpaster — Thu, 20 Aug 2026 12:56:06 +0000

Bioptimus to use Cancer Research Horizons’ data to train and evaluate its AI foundation model Third partnership since Bioptimus launched ground-breaking STELA initiative in March Deal adds Bioptimus’ first UK patient cohort to STELA, deepening its multimodal biology model Thursday August 20th 2026, Paris, FRANCE: Bioptimus, a global AI tech company pioneering the first world […]

The post Bioptimus partners with Cancer Research Horizons to advance AI-powered precision medicine first appeared on Tissuepathology.com.

Imagene AI Joins Proscia Ready Partner Alliance to Advance AI-Powered IHC Companion Diagnostics Development

Erica Goodpaster — Wed, 19 Aug 2026 13:21:52 +0000

Imagene AI: Integration with Proscia’s Concentriq platform will facilitate pharma companies, diagnostic assay and platform providers, and CROs in operationalizing companion diagnostic programs August 18, 2026 Imagene AI, a leader in AI-powered precision oncology, today announced that it has joined the Proscia Ready partner alliance. Imagene AI is collaborating with Proscia® to integrate its advanced […]

The post Imagene AI Joins Proscia Ready Partner Alliance to Advance AI-Powered IHC Companion Diagnostics Development first appeared on Tissuepathology.com.

Gilead and Nucleai probe why target-positive tumors can still resist ADCs

Erica Goodpaster — Tue, 18 Aug 2026 12:06:42 +0000

Nucleai, Gilead, and target-positive tumors Antibody-drug conjugates (ADCs) have emerged as one of the busiest and most crowded niches within oncology, given their potential to use an antibody to ferry a potent cytotoxic payload toward tumor cells. The class now spans about 15 FDA-approved products, and the segment is growing steadily. Evaluate Pharma projects the ADC category […]

The post Gilead and Nucleai probe why target-positive tumors can still resist ADCs first appeared on Tissuepathology.com.

Lumea Climbs the 2026 Inc. 5000 Ranking, Reflecting Continued Rapid Growth

Erica Goodpaster — Mon, 17 Aug 2026 12:19:28 +0000

Lumea: Company Recognized for Large Revenue Growth, Earning a Place Among the Nation’s Most Successful Independent Businesses LEHI, UT, UNITED STATES, August 11, 2026 /EINPresswire/ — Lumea today announced it has been ranked No. 1,641 on the 2026 Inc. 5000 list, the annual list of the fastest-growing private companies in America. Lumea also ranked No. […]

The post Lumea Climbs the 2026 Inc. 5000 Ranking, Reflecting Continued Rapid Growth first appeared on Tissuepathology.com.